Almotriptan

This page contains recent news articles, when available, and an overview of Almotriptan but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.


Overview:

Almotriptan
(when available)

Pharmacology and use:
Dihydrotachysterol is hydroxylated in the liver to 25-hydroxydihydrotachysterol, which is the major circulating active form of the drug. It does not undergo further hydroxylation by the kidney and therefore is the analogue of 1, 25-dihydroxyvitamin D. Dihydrotachysterol is effective in the elevation of serum calcium by stimulating intestinal calcium absorption and mobilizing bone calcium in the absence of parathyroid hormone and of functioning renal tissue. Dihydrotachysterol also increases renal phosphate excretion. Used for the treatment of acute, chronic, and latent forms of postoperative tetany, idiopathic tetany, and hypoparathyroidism

Mechanism Of Action:
Once hydroxylated to 25-hydroxydihydrotachysterol, the modified drug binds to the vitamin D receptor. The bound form of the vitamin D receptor serves a transcriptional regulator of bone matrix proteins, inducing the expression of osteocalcin and suppressing synthesis of type I collagen. Vitamin D (when bound to the vitamin D receptor) also stimulates the expression of a number of proteins involved in transporting calcium from the lumen of the intestine, across the epithelial cells and into blood. This stimulates intestinal calcium absorption and increases renal phosphate excretion. These are functions that are normally carried out by the parathyroid hormone.

News Articles on Vitamin D4 (Dihydrotachysterol)

Treating Headaches Depends on the Type of Pain  -  Nov 12, 2007
Migraine headaches respond very well to triptan-type medications like sumatriptan, rizatriptan, almotriptan, eletriptan and nonsteroidal drugs such as LA Downtown News Online,

Emne: Reward mechanisms they dont executives say doubled.  -  Jul 13, 2007
Oppland Arbeiderblad,Patients should hygiene is allopurinol to practice after about almotriptan alcohol. While all proceeding to disease burden alora subunits.

Stellar start on the stock market for Spain's Almirall  -  Jun 21, 2007
Pharma Times (subscription),The price seems cheap, given that the firm already has a successful range of drugs on the market, led by the migraine treatment Almorgran (almotriptan) and

The Medical Minute: Migraines  -  Jun 21, 2007
State College News,For more severe attacks, medications in the triptan family are the mainstay of treatment (eletriptan, sumatriptan, rizatriptan, almotriptan, zolmitriptan,

Early Treatment With Almotriptan Reduces Disability From Migraine ...  -  May 7, 2007
DG NewsBOSTON, MA -- May 7, 2007 -- Migraine sufferers achieve a pain-free state more quickly reduced disability with almotriptan than with placebo when treated

FDA Warns on Mixing Antidepressants with Migraine Drugs  Jul 20, 2006
Triptans were Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan) Maxalt and Maxalt-MLT (rizatriptan), Relpax (eletriptan ... -MedPage Today



Forest and Almirall Announce a Development and Marketing ...  10 Apr 2006
Almirall research products include AXERT9(R) (Almotriptan) for the treatment of migraine which was approved by the FDA in 2001 and is marketed by Ortho-McNeil ... - Finanzen.net

Early Treatment of Acute Migraine with Almotriptan Provides ...  Apr 5, 2006
SAN DIEGO, CA -- April 5 2006 -- Almotriptan 12.5 mg provides significant efficacy in the acute treatment of migraine, when administered within 1 hour of onset ... - DG News

BUSINESS BRIEFS: BRIEFS  Mar 25, 2006
The patent, on almotriptan, the main ingredient in Axert, expires in May 2015, according to the FDA's Web site. Teva obtained inside ... - Asbury Park Press

Brand Names/Synonyms:
Almotriptan is also known by the following brand names and/or synonymsAlmotriptan; Axert; Eletriptan

Drug Category:
Almotriptan is categorized under the following by the FDA: Anti-migraine Agents; Anti-inflammatory Agents; Vasoconstrictor Agents; Selective Serotonin Agonists; ATC:N02CC05

Dosage Forms:
TABLET

Absorption:
Not Available

Interactions:
-->Interactions for Almotriptan:

Ergot-Containing Drugs

These drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT® within 24 hours of each other should be avoided.

Monoamine Oxidase Inhibitors

Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%. No dose adjustment is necessary.

Other 5-HT1B/1D Agonists

Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT® is contraindicated.

Propanolol

The pharmacokinetics of almotriptan were not affected by coadministration of propranolol.

Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.

If concomitant treatment with AXERT® and an SSRI is clinically warranted, appropriate observation of the patient is advised.

Verapamil

Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan. No dose adjustment is necessary.

Ketoconazole and Other Potent CYP3A4 Inhibitors

Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan. Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.

Drug/Laboratory Test Interactions

AXERT® is not known to interfere with commonly employed clinical laboratory tests.






Chemical IUPAC Name:
N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]-ethanamine

:
 
Web health.mongabay.com



Health Home | Conditions | Cancer | Medications | Surgery | Vaccines

mongabay.com


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.


COPYRIGHT 2007 MONGABAY.COM